Sun Pharmaceutical Industries Ltd. closed 13.62% below its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

Discover the Sun Pharma Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed another inspection last month.

Trump pharma and chip tariffs may start this month, sparking price hikes, inflation, and global trade ripples.

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

Sun Pharmaceutical Industries Ltd. closed 14.19% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

U.S. inspectors have found new breakdowns at a Sun Pharmaceuticals plant in India that produces medications for U.S. customers, ProPublica reported July 16. The FDA found the factory failed to ...